Literature DB >> 16169065

Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas.

Nicholas P Taylor1, Randall K Gibb, Matthew A Powell, David G Mutch, Phyllis C Huettner, Paul J Goodfellow.   

Abstract

OBJECTIVES: A frameshift mutation in the double-strand breakage repair gene XRCC2 was identified in a mismatch repair (MMR) deficient cell line derived from a uterine carcinosarcoma. The frameshift mutation occurred in a mononucleotide run (poly-T tract), a target for strand-slippage mutation in MMR deficient tumors. We sought to determine if XRCC2 mutation is important to uterine carcinosarcoma tumorigenesis and whether the XRCC2 poly-T tract is a target for mutation in cells lacking MMR.
METHODS: MSI-typing was used to assess the MMR status of 30 primary carcinosarcomas. The entire XRCC2 coding region was sequenced in all tumors. Single strand conformational variant (SSCV) analysis was used to screen for poly-T tract mutation in 50 endometrioid adenocarcinomas with defective MMR.
RESULTS: Seven of 30 (23.3%) primary carcinosarcomas had an MSI-H phenotype. No XRCC2 coding mutations were identified in the 30 carcinosarcomas, and only one of the fifty MSI-H endometrioid adenocarcinomas had an XRCC2 poly-T tract mutation.
CONCLUSIONS: Despite the high frequency of mismatch repair deficiency in carcinosarcomas, no XRCC2 poly-T tract frameshift mutations were identified in these tumors. The fact that only one of 50 additional MSI-H tumors had a frameshift mutation suggests that the XRCC2 poly-T tract is not a frequent target for defective MMR. The absence of coding sequence mutations in primary carcinosarcomas suggests that XRCC2 defects are unlikely to play a significant role in carcinosarcoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169065     DOI: 10.1016/j.ygyno.2005.07.130

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Effects of somatic alterations at pathway level are more mechanism-explanatory and clinically applicable to quantity of liver metastases of colorectal cancer.

Authors:  Zhong-Guo Zhang; Fei Ma; Shuang Zhao; Xiaoyu Yang; Fang Liu; Chenghai Xue; Liren Liu; Jin Gu; Haozhe Piao
Journal:  Cancer Med       Date:  2019-06-20       Impact factor: 4.452

2.  MLH1 promoter hypermethylation in uterine carcinosarcoma rarely coexists with TP53 mutation.

Authors:  Michal Kunc; Anna Gabrych; Bartlomiej Rekawiecki; Adam Gorczynski; Sabine Franke; Johannes Haybaeck; Wojciech Biernat; Piotr Czapiewski
Journal:  Contemp Oncol (Pozn)       Date:  2019-11-07

3.  Analysis of somatic microsatellite indels identifies driver events in human tumors.

Authors:  Yosef E Maruvka; Kent W Mouw; Rosa Karlic; Prasanna Parasuraman; Atanas Kamburov; Paz Polak; Nicholas J Haradhvala; Julian M Hess; Esther Rheinbay; Yehuda Brody; Amnon Koren; Lior Z Braunstein; Alan D'Andrea; Michael S Lawrence; Adam Bass; Andre Bernards; Franziska Michor; Gad Getz
Journal:  Nat Biotechnol       Date:  2017-09-11       Impact factor: 68.164

4.  Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma.

Authors:  Michał Kunc; Anna Gabrych; Bartłomiej Rękawiecki; Adam Gorczyński; Johannes Haybaeck; Wojciech Biernat; Piotr Czapiewski
Journal:  Contemp Oncol (Pozn)       Date:  2020-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.